Use of cannabinoids in the treatment of epilepsy
AssigneeGW Research Limited
InventorVolker KNAPPERTZ
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Claims19
A method of treating seizures in a patient in need thereof, comprising administering to the patient cannabidiol (CBD) drug substance having a purity of at least 95% (w/w) CBD, wherein the patient is administered a starting dose of CBD of 5 mg/kg/day, and about 3 or about 4 days after administering the starting dose, the starting dose is increased by about 1-5 mg/kg.
Dependencies are inferred from the claim text.